• Psychedelic Medicine

CANCER | +80 articles

mental-health-benefits-from-one-dose-of-psychedelic-drug-last-for-years-in-people-with-cancer-330173-1280x720.webp


Mental Health benefits from one dose of psilocybin last for years in people with cancer

New York University | Technology Networks | 19 Jan 2022

Following up on their landmark 2016 study, researchers at NYU Grossman School of Medicine found that a one-time, single-dose treatment of psilocybin, a compound found in psychedelic mushrooms, combined with psychotherapy appears to be associated with significant improvements in emotional and existential distress in cancer patients. These effects persisted nearly five years after the drug was administered.

In the original study, published in the Journal of Psychopharmacology, psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreases in cancer-related demoralization and hopelessness, improved spiritual well-being, and increased quality of life. At the final 6.5-month follow-up assessment, psilocybin was associated with enduring antianxiety and antidepressant effects. Approximately 60 percent to 80 percent of participants continued with clinically significant reductions in depression or anxiety, sustained benefits in existential distress and quality of life, as well as improved attitudes toward death.

The present study, publishing online Jan. 28 in the same journal, is a long-term follow-up (with assessments at about 3 years and 4.5 years following single-dose psilocybin administration) of a subset of participants from the original trial. The study reports on sustained reductions in anxiety, depression, hopelessness, demoralization, and death anxiety at both follow-up points.

Approximately 60 percent to 80 percent of participants met criteria for clinically significant antidepressant or anxiolytic responses at the 4.5 year follow-up. Participants overwhelmingly (71 to 100 percent) attributed positive life changes to the psilocybin-assisted therapy experience and rated it among the most personally meaningful and spiritually significant experiences of their lives.

"Adding to evidence dating back as early as the 1950s, our findings strongly suggest that psilocybin therapy is a promising means of improving the emotional, psychological, and spiritual well-being of patients with life-threatening cancer," says the 2016 parent study's lead investigator, Stephen Ross, MD, an associate professor of psychiatry in the Department of Psychiatry at NYU Langone Health. "This approach has the potential to produce a paradigm shift in the psychological and existential care of patients with cancer, especially those with terminal illness."

An alternative means of treating cancer-related anxiety and depression is urgently needed, says Ross. According to statistics from several sources, close to 40 percent of the global population will be diagnosed with cancer in their lifetime, with a third of those individuals developing anxiety, depression, and other forms of distress as a result. These conditions, experts say, are associated with poorer quality of life, increased rates of suicide, and lowered survival rate. Unfortunately, conventional pharmacologic treatment methods like antidepressants work for less than half of cancer patients and tend to not work any better than placebos. In addition, they have no effect whatsoever on existential distress and death anxiety, which commonly accompany a cancer diagnosis and are linked to a hastened desire for death and increased suicidality, says Ross.

The researchers say psilocybin may provide a useful tool for enhancing the effectiveness of psychotherapy and ultimately relieving these symptoms. Although the precise mechanisms are not fully understood, experts believe that the drug can make the brain more flexible and receptive to new ideas and thought patterns. In addition, previous research indicates that the drug targets a network of the brain, the default mode network, which becomes activated when we engage in self-reflection and mind wandering, and which helps to create our sense of self and sense of coherent narrative identity. In patients with anxiety and depression, this network becomes hyperactive and is associated with rumination, worry, and rigid thinking. Psilocybin appears to acutely shift activity in this network and helps people to take a more broadened perspective on their behaviors and lives.

How the original research and follow-up were conducted

For the original study, the NYU Langone team provided 29 cancer patients with nine psychotherapy sessions, as well a single dose of either psilocybin or an active placebo, niacin, which can produce a physical flush sensation that mimics a psychedelic drug experience. After seven weeks, all participants swapped treatments and were monitored with clinical outcome measures for anxiety, depression, and existential distress, among other factors.

Although researchers found that the treatment's antianxiety and antidepressant qualities persisted 6.5 months after the intervention, little was known of the drug's effectiveness in the long term. The new follow-up study is the longest-spanning exploration of psilocybin's effects on cancer-related psychiatric distress to date, the study authors say.

"These results may shed light on how the positive effects of a single dose of psilocybin persist for so long," says Gabby Agin-Liebes, PhD candidate, lead investigator and lead author of the long-term follow-up study, and co-author of the 2016 parent study. "The drug seems to facilitate a deep, meaningful experience that stays with a person and can fundamentally change his or her mindset and outlook," she says.

Agin-Liebes, who is pursuing her PhD in clinical psychology at Palo Alto University in California, cautions that "psilocybin does not inherently lead to positive therapeutic effects when used in isolation, and in uncontrolled, recreational settings, and should be taken in a controlled and psychologically safe setting, preferably in conjunction with counseling from trained mental health practitioners or facilitators," she adds.

Next, the researchers plan to expand this research with larger trials in patients from diverse socioeconomic and ethnic groups who have advanced cancer-related psychiatric and existential distress.

"This could profoundly transform the psycho-oncologic care of patients with cancer, and importantly could be used in hospice settings to help terminally ill cancer patients approach death with improved emotional and spiritual well-being," says Ross.

 
Last edited:
shutterstock_1851505357-750x430.jpg



Psychedelics and their promise in treating anxiety and depression in cancer patients, study*

by Patrick Ryan | The Dales Report | 2 Feb 2, 2022

Reports pertaining to the clinical study of psychedelics used to treat cancer indicate the analysis might prove to be a game changer. Cancer is a problem for reasons beyond physical deterioration. Cancer also causes anxiety and depression. Though antidepressants are available to cancer patients, they do not always lift the spirit as intended. Enter psychedelic drugs.

As time progresses, more medical professionals agree it is not prudent for patients to use traditional medications to treat depression and/or anxiety stemming from cancer. Rather, a nontraditional treatment such as psychedelics might be optimal. Experimental treatment with the use of psychedelics shows promise in the treatment of anxiety stemming from a cancer diagnosis and ensuing battle. In particular, group psychedelic therapy has the potential to help patients stay positive and move forward.

The hope is that group psychotherapy in unison with psilocybin, the key component of magic mushrooms, will help patients better handle the prospect of death stemming from cancer. Some medical professionals researching the use of psychedelics for cancer patient treatment indicate they are the only treatment modality that makes a meaningful difference in regard to alleviating distress.

Research details

Psychedelics such as LSD and psilocybin were studied at length by scientists dating back to the 50s. Initial research showed the drugs had considerable promise in the context of treating cancer patients’ existential distress. Psychedelic research advances in the prior two decades has expanded on the initial studies. Dr. Paul Thielking is at the center of this research effort.

Thielking assisted in the design of Huntsman’s psychedelic clinical trial, serving as the lead therapist of the project. Thielking is adamant that psychedelics will prove essential to patients’ end-of-life care. He insists it merely takes one psychedelic dose for some patients to enjoy transformative experiences. Psychedelics brighten patients’ outlook on life and ultimately improve the human condition while battling cancer and confronting the prospect of death. Perhaps just as important is the fact that those positive benefits have staying power.

As an example, a recent study of psychedelics’ long-term effects on cancer patients reveals this alternative treatment modality reduces depression and anxiety across a period of four years after the initial dose.

Obstacles in the way of psychedelic use

If psychedelics are approved for cancer patient use, they will benefit hundreds of thousands of individuals. However, there are some impediments. As an example, the Controlled Substances Act passed in 1970 lists psychedelics as a Schedule 1 drug, meaning it is grouped with other restricted drugs. However, if scientific evidence continues to destigmatize the use of psychedelics, the drugs might be rescheduled.

The rescheduling of psilocybin and other psychedelics sets the stage for cancer patients and others to use these alternative treatment modalities to improve their quality of life. However, such a rescheduling will ultimately hinge on the results of clinical trials. Clinical trials require authorization from the United States Food and Drug Administration. If those trials are approved and show promise, the focus will shift to their administration. There is still a question as to whether group therapy or individual therapy with the use of psychedelics is the best approach.

Psychedelics investors are encouraged to stay tuned. The progression of psychedelic treatments will continue to take shape in the months ahead.

*From the article here :
 
Last edited:
cannabis_cancer_treatment.jpg


Cannabis and Cancer Treatment*

by Liz Jarrard & Dr. Lynn Marie Morski, MD, Esq | Psychable | 21 Feb 2022

In recent years, scientists have created many innovations for treating symptoms of cancer and cancer-related ailments. Sometimes, help and hope grow from the most unexpected places.

Cannabis, or marijuana, is well known as a recreational drug. More recently, cannabis has been used for many medicinal purposes, including as a pain-killer, and it has been found to help reduce anxiety and inflammation. Now there is new research that suggests that compounds called cannabinoids, derived from the cannabis sativa plant, may be able to treat cancer.

The biology of cancer

Cancer does not discriminate by race, class, religion, or age. Cancer can afflict anyone in their prime, or steal the life of a child, leaving loved ones devastated in its wake. Some signs of cancer are so minor, they often go completely unnoticed until the cancer has spread. Loved ones or friends may even notice signs or symptoms before a cancer patient does.

Certain types of cancer are considered mostly preventable. Preventable cancers are linked to modifiable risk factors, which can be decreased by following a healthy lifestyle. Avoiding risky behaviors or exposure to carcinogens (cancer-causing agents) also modifies cancer risks. Of all cancers, breast, cervical, lung, and liver cancer are some of the most preventable. When left undetected and untreated, however, these cancers are also among the deadliest.

The American Institute of Cancer Research (AICR) explains that several factors point to a higher risk of getting the most preventable types of cancer:​
  • Age: The older a patient is are, the greater the risk for breast cancer;​
  • Body Mass Index: carrying excess body fat increases the risk for cancer;​
  • Family history: Inheriting cancer genes does increase risk, but living a healthy lifestyle can mitigate some of these risks.​
  • Physical activity: Being active decreases risks for many types of cancer. For instance, vigorous regular physical activity decreases the risk for premenopausal breast cancer.​
Cancer stage and potential cannabis treatment

The stage of a cancer is the most important factor for cancer prognosis. In general, the earlier cancer is detected, the better the prognosis will be. To determine a patient’s cancer stage, a pathologist studies cells, tumor, organ tissue, and any lymph nodes removed for biopsy.

The three-stage TNM system of cancer staging involves:​
  • T = Tumor size​
  • N = Lymph Node status (the number and location of lymph nodes with cancer)​
  • M = Metastases (cancer that has spread from initial cancer sites)​
Cancer pathologists also look for other factors that determine stage and severity, such as tumor grade, and hormone receptor status.

The stages of cancer range from 0 to IV (0 to 4) with the highest stage (stage IV) having the poorest prognosis. Stage IV means any cancer with metastases. If the cancer has spread from an initial site, it can be the most life-threatening, regardless of the size of the tumor, the lymph node status, or any other factors.

Apoptosis is a mechanism the body uses to efficiently eliminate dysfunctional cells; in this case, cancerous cells. If the body is efficiently eliminating dysfunctional cancerous cells, cancer cannot grow and spread.

Cancer cells carry damaged DNA that replicates as part of the cell’s life cycle. These damaged cells should be eliminated by apoptosis, but for various reasons continue to divide and multiply. These cancer cells grow into tumors and spread throughout the body. The earlier these cancer cells are targeted, the better chance the cancer patient has at eliminating these cells from the body before they metastasize.

Regardless of cancer stage, cannabis may be used to treat various symptoms and even reduce the size of tumor growth. And cannabis may be used as a therapy to treat cancer symptoms, like pain, at any stage of a cancer diagnosis.

So how exactly is cannabis effective against cancer? The next section discusses how cannabis can directly target cancer cells.

Cannabis and targeted cancer cell death

Cannabinoids are the derivatives, or components of the cannabis sativa plant. Cannabinoids interact with human physiology, and are considered biologically active. The two cannabinoids we know most about are delta-9-tetrahydrocannabinol, better known as THC, and cannabidiol, or CBD.

Cannabis has been researched as a possible treatment for killing cancer cells before they develop into tumors that can metastasize. The cannabinoid CBD can be used as a concentrated therapy to target certain mechanisms that promote cancer cell death (apoptosis).

Recent studies show promise in the use of cannabidiol to fight breast cancer specifically by inhibiting cell growth and promoting cancer cell death.

Researchers are exploring various ways that cannabidiol oil (or CBD oil) can be used to help regulate apoptosis. One study involving lung cancer in mice showed evidence that cannabinoids inhibited tumor cell growth and prolonged the life of the subjects.

Subsequent studies indicated that CBD slowed cell growth and induced cell death by modulating cell signaling pathways in cancer cells. In other words, some researchers believe cannabis helps kill or at least inhibit the growth of cancerous cells.

A 2007 study published in the journal Molecular Cancer Therapeutics showed that CBD could slow or even stop the progression of metastatic breast cancer. In the study, the team led by senior scientist Dr. Sean D. McAllister used CBD to inhibit the activity of the Id-1 gene, believed to be responsible for cancer cells becoming more aggressive and metastatic.

The study was done in a lab on cells, not humans, which could yield different results. This study reported that CBD could be a potential treatment to slow the growth of cancer cells and reduce the invasiveness of aggressive, metastatic cancers that currently respond to few available treatments.

Further animal studies found that cannabinoids may have anti-tumor effects, but more research is needed to fully understand the mechanisms of how these plant compounds can influence the biology of cancer.

Conclusion

At this stage, it’s too soon to say that cannabis can treat cancer directly as a targeted treatment. For now, like other alternative or holistic therapies, cannabis should only be used as a complement to your prescribed course of treatment, if at all.

However, many people report cannabis helps alleviate the nausea and pain associated with chemotherapy. Some patients have also had success using cannabis to address the nerve pain associated with chemo-induced peripheral neuropathy.

As with any cancer, the sooner there is a diagnosis, the better. Watch for signs and symptoms, and adapt your lifestyle to reduce risks.

*From the article here :
 
Last edited:

1200px-Central_Californian_Coastline%2C_Big_Sur_-_May_2013.jpg


Psychedelics may ease cancer patients’ depression, anxiety

These drugs were banned decades ago. My clinical trial suggests they might have a meaningful, positive effect in treating mood issues.

by Manish Agrawal | Washington Post | 2 Ape 2022

Throughout my medical training and more than 20 years as a practicing oncologist, the emphasis in cancer treatment has always been on treating the tumor. But I also know that my patients’ suffering extends far beyond the physical. Over time, the deep, emotional distress that turns their lives upside down has gone from a whisper of concern to a deafening, unavoidable blast.

Those of us who treat cancer patients cannot deny the painful emotions they and their families experience. Facing that reality includes looking for practical, effective ways of easing the pain. The trouble is the tools to address the emotional dimensions of cancer have been scant.

That began to change a few years ago when evidence emerged indicating that psychedelics could reduce death-anxiety that many cancer patients experience. In the United States, more than 90 clinical trials are exploring whether one of these substances — psilocybin, a natural hallucinogenic found in certain mushrooms — can give patients the emotional relief they desperately seek.

Along with my work as an oncology clinician, I’m the principal investigator for one of those trials. Our trial is suggesting that these drugs, which were banned decades ago, might have a meaningful, positive effect in treating major depression, anxiety other mood issues.
‘Acid Test’: The case for using psychedelics to treat PTSD, depression

Dramatic changes

One patient with metastatic cancer, who has suffered from severe emotional distress because of her difficult diagnosis and treatment, decided to participate last year in the clinical trial my colleagues and I were conducting. She found that shortly after a single psilocybin therapy session her life and perspective changed dramatically.
Her session had been quite challenging in contrast to the typical mystical experience some have recounted; she faced her death directly, which she found to be painful. Then, while at her lake house a day after her psilocybin session, as the light was fading into darkness and the chirping of crickets rose to a crescendo, she felt a blanket of peace envelop her, and she arrived at an insight: All these crickets would inevitably soon die and a new crop of them will take their place. It reminded her that, when she was born, she was replacing others who had died, and, with her death, others will come after her. All this was a part of the natural cycle.

This feeling of being part of something greater than herself, of seeing how she fit into the complex puzzle of nature, helped her place her fast-approaching mortality in a larger context and with that the heavy weight of anxiety about her death lifted.

In the past, I might have said to her, “Dying is natural; it’s part of the human experience,” but without this experience, it would not have landed well. She had to feel this in her whole person, not just as an intellectual or philosophical exercise. By her own account, it was an experience that she had never had before and that lasted for many weeks and months more. She could only attribute her dramatic change only to her psilocybin treatment.

Another trial participant recalled during her psilocybin session a scene in nature where she saw trees that had died and were filled with living organisms and nutrients that allowed younger trees to feed and grow. It left her feeling that, even after her death, she would leave to her children a legacy that provides them with emotional and spiritual support.
Promising evidence

Results from the clinical trials my colleagues and I conducted have not yet been published, so it is too soon to make any definitive conclusions about the use of psilocybin for treatment of depression. But the pre-publication evidence is promising: half of all the 30 participants no longer had clinical depression eight weeks after a single dose of psilocybin and accompanying therapy, and 80 percent of the people studied had their depression scores drop by at least 50 percent. (The trial measured depression with the Montgomery-Asberg Depression Rating Scale, or MADRS.)

These clinically significant results are consistent with a growing number of other studies on psychedelics’ effect on illnesses, such as depression and post-traumatic stress disorder. One small study from Imperial College London, reported in the New England Journal of Medicine last year, suggested that psilocybin could ease symptoms of major depressive disorder (or MDD) at least as effectively as a conventional selective serotonin reuptake inhibitor antidepressant — but with potentially fewer side effects. Another study, conducted at Johns Hopkins Bayview Medical Center, indicated that psilocybin treatments provided relief from MDD among cancer patients and others. And a study published last year concluded that the psychedelic drug MDMA “represents a potential breakthrough treatment” for PTSD.
Ecstasy could be ‘breakthrough’ therapy for soldiers, others suffering from PTSD

The promise of psychedelic therapy is significant for not only patients but also clinicians like me who have exhausted our arsen
al to help those crushed by the emotional burden of cancer.

Intense psychological agony

Oncologists are well-equipped to fight the physical threats of cancer with powerful, yet sometimes-imperfect tools including chemotherapy, radiation and surgery, but they often feel helpless when it comes to treating the intense psychological agony many patients experience.

Many of the approved therapies to treat my cancer patients’ mental health don’t help them. Not surprisingly, research has shown a high degree of depression and burnout among oncologists as well, some of which stems from watching patients suffer and not being able to help.

Clinical trials studying psilocybin and MDMA are now picking up where others left off before 1970, when the federal government passed the Controlled Substances Act that banned the use of and even research into psychedelics. They’re finding that, for some people, even a single dose of psilocybin in a supportive environment — accompanied by therapy — may be more impactful and have longer lasting effects than current protocols: talk therapy combined with existing antidepressant drugs.

Like many of my colleagues, I was initially skeptical about embracing psychedelics, which many see as easily abused recreational drugs. But the growing evidence from rigorous research has caused many physicians, like me, to reassess. In the trials at our center, we provide treatment within a highly controlled, safe environment. The format is the opposite of a traditional “take two of these and call me in the morning” form of care.

Trial participants are screened based on a set of inclusionary and exclusionary criteria and meet for hours before their session with our well-trained therapists. And a team closely monitors the administration of the treatment, sitting with each patient until the effects of the drug completely wear off. There are then several meetings after the session to help integrate the psilocybin session, so the insights and experience gained continue to have benefit.

The research is also helping to diminish concerns many have about the potential for the abuse of psychedelics. While abuse is always possible, developing standards of care and rigorous training criteria help assure that trial participants and future patients are getting safe and qualified care.

One of the messages I share with patients is that the deep distress and the dark feelings they experience after being diagnosed with cancer are normal and deserve as much attention as the physical effects of their cancer. Patients should not have to go somewhere outside the cancer treatment center to get that help.

If further research into psychedelic therapy is validated and approved by the Food and Drug Administration, I think cancer centers would do well to offer it as part of an in-house continuum of cancer care. Besides chemotherapy and radiation, oncologists must work to address the psychological issues their patients face.

I have never witnessed the sort of dramatic response to any medical intervention as I have with some patients through psychedelic-assisted therapy. It is not a magic bullet or cure for a cancer patient’s suffering — and it won’t change their prognosis or life expectancy. But it could be a spark that begins their healing journey, helping them come to terms with their most difficult fears.

Manish Agrawal is an oncologist for Maryland Oncology Hematology at the Aquilino Cancer Center in Rockville, Md., where he is medical director. In 2021, he helped launch Sunstone Therapies, whose mission is to address the emotional effects of cancer diagnoses.

 
Last edited:
Centerpiece.PsychedelicsPart2.Final.jpg



One man's psychedelic journey to confront his cancer

by Paul Frysh | WebMD | 4 Jan 2022

Pradeep Bansal considered the five capsules he was about to swallow. Together they made up a 25 milligram dose of a substance that, in another setting, could have landed him in federal prison.

The substance was psilocybin, the active ingredient in magic mushrooms. To be more exact, it was a synthetic form of psilocybin called COMP360, made to pharmaceutical standards by a company called COMPASS Pathways. He was taking it as part of an FDA-approved clinical study on mental health therapy for people with cancer.

280x340_pradeep_bansal_headshot.jpg

Pradeep Bansal, MD

Bansal, a New York gastroenterologist, was far more comfortable giving medical treatment than receiving it. But he was getting used to it.

He had already been through surgery and a number of other treatments to address the physical aspects of his cancer. The psilocybin was to address the mental aspects -- the crushing anxiety and depression that had stuck with him after his diagnosis.

Bansal did not arrive at this moment lightly.

"I was extremely skeptical going into this process," says Bansal, who during a long medical career had looked with distrust and even disdain at alternative therapies.

"I don't have much patience for holistic medicine, homeopathy, acupuncture, or alternative medicines with claims of spiritual upliftment or altered states of mind."

But Bansal had done his homework on psilocybin and was impressed.

People with late-stage cancer and other serious health conditions who got psilocybin-assisted psychotherapy had "significant decreases" in anxiety and depression as long as 12 months after the treatment, according to studies published in 2011, 2014, and 2016.

One study from Johns Hopkins University tracked the effects of a single guided dose of psilocybin in terminal cancer patients with anxiety and depression. More than 80% had a "significant decrease" in symptoms -- even 6 months after treatment -- with more than 60% of the group remaining in the normal mood range.

For the study Bansal joined, there had been weeks of screening and consultation and preparation in a strictly controlled scientific trial.

And yet even with all that he had learned, even with his psychiatrist-guide by his side, he was afraid. Afraid of what he might experience under the powerful effects of psilocybin. And afraid that this was all a misguided waste of time -- that his mental angst would still be there when it was all over.

He knew that psilocybin, like other psychedelic substances, could take you on a "trip" -- could remove you, at least for a time, from normal conscious experience.

Maybe he would feel "funny," he thought. Maybe he would have some hallucinations. But how would that change the reality of his cancer?

How would it lift the black dread and anxiety he felt about his future?

Stuck in a dark place

Bansal had first noticed blood in his urine -- a lot of it -- in September 2019.

Two months later, doctors diagnosed cancer in his right kidney. He would need surgery to remove the kidney and surrounding lymph nodes (an operation called radical nephrectomy).

It was a shock, says Bansal. But the diagnosis and the surgery happened so quickly that he hardly had time to think. And treatment results seemed good. The cancer was only in stage I and the CT scans showed no signs of cancer after surgery.

"We were so relieved. Everyone was so happy," Bansal says. "They didn't even give me chemotherapy after surgery because it seemed so early."

But a routine scan in June 2020 revealed more cancer in his lung. Within a couple of months, it was in his bladder too.

"It was devastating," Bansal says. "I went from thinking I was healthy again to stage IV cancer."

As doctors scheduled surgery to remove part of his lung, Bansal started on painful immunotherapy (BCG therapy) for his bladder.

At this point, from a psychological standpoint, Bansal was reeling. As a doctor, he knew all too well the meaning of stage IV cancer.

With two adult children and a grandchild on the way, Bansal had been looking forward to retirement with his wife of almost 40 years. "Suddenly, I wasn't sure I was going to last that long," Bansal recalls.

"I was in a very dark place. I was very anxious, very depressed from lack of sleep."

He saw a therapist about his cancer diagnosis and maintained his regular meditation practice at home. He hired a personal trainer and tried to focus on any good news that he got about his treatment.

Those things helped, but not enough.

The basic facts were inescapable. His cancer might end everything. He couldn't stop thinking about it. And then he couldn't stop thinking about how he couldn't stop thinking about it.

If the worst happened, he didn't want to spend his last days in a state of such relentless existential angst. And it wasn't just for himself. He wanted to be strong and mentally present for his family and his loved ones and his patients.

As he searched for something to ease his mental anguish, Bansal recalled some psychedelic research on end-of-life anxiety and depression that he'd read about in Michael Pollan's 2018 book on psychedelics, How to Change Your Mind.

The studies were small and the research was new, but Bansal was impressed enough with the results to take a chance. He called a lead researcher of one of the studies, a fellow New York doctor, and eventually found himself accepted into a new study.

Starting the journey

By the time Bansal arrived at the Bill Richards Center for Healing at the Aquilino Cancer Center in Rockville, MD, he had already been through weeks of screening.

The main requirements for the study were a cancer diagnosis and a measurable level of depression. But study participants also had to be physically fit enough to handle the medication, and psychologically free from a personal or family history of psychosis or schizophrenia. (The study also required participants to slowly wean themselves from medications like SSRIs for depression or anti-anxiety medications under the strict supervision of a qualified doctor.)

Bansal's week of treatment began almost immediately on arrival at Aquilino. Everything was carefully choreographed but not rushed. From Monday through Wednesday, doctors followed his physical health with exams, ECGs, and blood work. And most importantly, they began to prepare him for the "dosing session" on Thursday when he would take the psilocybin.

This is the careful crafting of "set and setting" stressed in so many psychedelic therapies. "Set" refers to your mindset going into the drug experience. "Setting" is the space and people around you when the drug sends you into an altered state of consciousness.

Bansal met several times with at least three therapists in the days leading up to his dosing. He attended 4-plus hours of therapist-led group sessions with other people who would get a dosing on the same day. Together, they talked about what to expect during the experience and what to do in the face of fear or panic.

He connected with a therapist who would be his personal guide. Bansal's therapist was a military psychiatrist with over 30 years' experience.

"He was there with me from day 1, and so we established a relationship," Bansal says.

"He asked me a lot of personal background history -- you know, my religious convictions, aspirations, all those things."

"Trust and let go," was a kind of mantra for the treatment repeated by his guide and other doctors.

For Bansal, a doctor and scientist accustomed to using hard facts rather than touchy-feely slogans to navigate the care of patients, it was an adjustment, to say the least.

But he did his best to set aside his doubts and embrace the journey he was about to take.

The day of the trip

Thursday morning finally arrived. The setting of the dosing room was warm and welcoming, more like a cozy home study than a hospital room.

This matters more than you might think. First, because it's important that you feel safe, open, and comfortable enough to let go and enter into a therapeutic process. But also because though rare, it's possible -- especially with psilocybin -- for people to lose track of where they are and what they're doing and put themselves or others in danger.

The dose, 25 milligrams, had been carefully calibrated to induce a psychedelic experience sufficient for therapy. Much less than that, say 10 milligrams, isn't enough for most people to enter this state. A double dose, 50 milligrams, though not physically unsafe, may leave you too incoherent to have the useful insights key to therapeutic value.

A doctor, the lead investigator of the study, brought the five capsules into the room in an intricately carved crucible with a small ceremonial cup that held the water with which to take it.

"It was very solemn," Bansal says. "He sat down with me in a very calming way."

The doctor said: "Don't worry about it. Just trust and let go."

And that's just what he did.

Bansal swallowed the capsules and lay down. The doctor quietly left the room so that Bansal and his psychiatrist guide could begin their session together.

Special eye shades kept him in the pitch dark whether his eyes were open or closed. Headphones streamed a curated musical playlist - much of it Western classical like Strauss, Bach, Mozart, and Beethoven -- but also modern electronica and other music from cultures around the globe.

Bansal would remain here, with his therapist-guide by his side, in largely this same position, for the next 7-and-a-half hours.

It took about 45 minutes for the medication to kick in.

280x340_agrawal.jpg

Manish Agrawal, MD

The investigator

The doctor who brought the capsules into the dosing room was Manish Agrawal, MD, co-director of clinical research at the Aquilino Cancer Center and lead investigator of the study.

Agrawal trained at the National Cancer Institute and practiced for many years as an oncologist before developing an interest in psychedelic therapies. It was his work with cancer patients that drew him to psychedelics in the first place.

He had seen too many of his patients mentally wrecked by a cancer diagnosis, and he often felt helpless to comfort them.

"You take care of the physical aspects of the cancer, right? You talk about side effects and recommend another scan to look for recurrence."

"But what about the psychological effects?"


They can be very serious and too often go ignored, says Agrawal. Your plans for the future suddenly become moot. You may be concerned about your ability to work or worried about the pain and suffering and financial strain that might be ahead for both you and your family. And to top it all off, you're staring into the face of your own mortality.

So it's no wonder, says Agrawal, that many people develop clinical levels of anxiety and depression after a cancer diagnosis.

Like Bansal, Agrawal had been impressed by early studies on psilocybin-assisted therapies for end-of-life anxiety and depression. He had tried other approaches -- support groups, one-on-one therapy, religious counselors, psychiatrist-prescribed medication -- but he was never really happy with the results.

To Agrawal, psilocybin-assisted therapy was the first thing that looked like it could really make a difference.

And so after his psychedelic certification at the California Institute of Integral Studies (CIIS), Agrawal was determined to change his approach.

Pre-publication results for Agrawal's study show half of all participants no longer had clinical depression 8 weeks after a single dose of psilocybin and accompanying therapy. And about 80% of the people studied had their depression scores drop by at least 50%. (The trial measured depression with the Montgomery-Asberg Depression Rating Scale, or MADRS.

The result was The Bill Richards Center for Healing at Aquilino Cancer Center, built specifically to study psychedelic-assisted therapies for psychological distress in people with cancer. The mission of the center is to help develop safe, FDA-approved psychedelic therapies for the mental health of cancer patients, and, once approved, provide a state-of-the-art facility and staff to administer those treatments.

A trip into the unknown

Back in the dosing room, Bansal was starting to feel the effects of the medication. As the psilocybin kicked in, spectacular images swirled.

"It was as if a million stained glass windows had suddenly come to life and were dancing in front of my vision," Bansal says.

There were moving landscapes and intricate swirling patterns and massive stages in the sky where he saw orchestras playing the music he was hearing.

Bansal saw himself being crushed by a huge machine and buried, dead, in the Earth. He died and returned to life several times, glided over the top of New York City with the skyscrapers just below him, and took in the vision of the entire universe.

"I saw this expanse of the sky that was limitless. And there was this prehistoric reptile creature that spanned galaxies in the sky ahead of me who was dying. I said, 'My God, the universe is dying,' but then after a few moments, the universe came to life again in a burst of stars exploding."

All the while, Bansal says, he was well aware that it was simply his mind creating these images, thoughts, and ideas. He knew he was in a safe room wearing eyeshades and headphones.

And yet, he says, it felt true. "The images and feelings are so powerful that you cannot help but believe they are in some way a part of reality."

"At one point, I saw this giant Ferris wheel coming towards me and it was full of giant crabs, clicking and clacking their pincers. And my brain told me, 'That's my cancer!'"


Bansal was terrified. But he and his therapist had arranged a system of signals before the session. "If I was feeling afraid, I would hold his hand and if I had other issues, I would raise my hand. If I was feeling good, I would give him a thumbs up."

Bansal reached out to his therapist and grasped his hand. "I said, 'My cancer is coming at me!'"

His therapist was clear about what to do: Stand firm and walk toward it.

"That's what they tell you: If you see anything frightening, you face it. And that's the whole point of this exercise. And so, I stood and walked forward, and it just blew off in a puff of smoke."

A state of peace

Around 3 hours into the experience, Bansal started to feel an immense sense of peace, happiness, and even comfort.

"I felt like I was watching a movie or a multidimensional slideshow. I was also a part of the movie. I felt like I could tell my mind what I wanted to see, and it would show it to me. It's almost like you can mold your own visions. It was mystical."

After about 8 hours, as the effects of the drug wore off, Bansal removed his eyeshades and headphones. He was completely drained.

"Even though I was lying down on my back for 7 hours, I felt like I had been run over by a truck. I was exhausted beyond belief physically and mentally."

This was partly due to the fact that he hadn't eaten much during the session. But mostly, says Bansal, it was due to the searing emotional intensity of the experience.

After the journey

It's hard to put into words, says Bansal, what this treatment has done for his life. He feels as if he has stumbled onto something very precious that had been right in front of him all along. He wrote of his change in perspective almost obsessively in his journal in the days and weeks after treatment. One passage reads:

"It seems that as time is passing on, I'm becoming more relaxed and hopeful, more calm, and at peace. Family has become even more important to me now. Money, politics, material gains, alcohol, seem less important."

And yet there was nothing "easy" about the experience. In fact, in some ways the experience demanded more from him.

"I feel I need to be more compassionate and considerate -- less irritable and angry, more understanding of others' needs. I feel I need to be a better human being, a better patient, a better father, and a better doctor for my patients."

The experience, he says, gave him something far more important than mere ease. It gave him a sense of meaning.

"How many sorrows in the universe? My cancer is nothing. Life does not end with the end of life. What was will be again. Eternally."

From his journal:

"I died, and I was reborn. If I survived this, then I can face anything and anybody in the cosmic scheme. I can become part of it."

"How many sorrows in the universe? My cancer is nothing. Life does not end with the end of life. What was will be again. Eternally."


That's not an unusual response, according to the namesake of The Bill Richards Center for Healing. Richards, PhD, has worked in the world of psychedelic-assisted psychotherapy since 1963.

A psychologist with decades of experience, Richards and his colleagues figure that, with few possible exceptions, he has helped treat more people with psychedelic therapies than anyone alive in Western medicine today. At Aquilino, he works directly with patients and oversees the therapy protocol that goes along with the psilocybin dosing sessions.

"It's inspiring," Richards says.

"You meet someone who's very depressed and scared and isolating from family and having all kinds of physical complaints. And a few days later, you talk to the same person and they have a whole new lease on life."

"And the positive effects can extend deep into the family system,"
he says.

After psilocybin treatment, says Richards, the person with cancer can become a kind of social worker for the family. They're often far better able to talk about death and loss and even money and family issues than their loved ones. It's not uncommon after treatment to see the resolution of years-old resentments or grievances that have dogged a family for many years.

Plus, says Richards, the cancer patient often ends up as a kind model to other family members for how to approach death. "They can demonstrate how to live fully -- right to the last breath -- which is a real gift because those relatives and loved ones have to die someday too, you know."

At 80 years old, Richards is still in active practice and hopes to spend the rest of his days working with people in end-of-life care.

After the experience

Psychedelic-assisted therapy does not end with the dosing session. Integration sessions, where you discuss what happened during the dosing session, are a key part of most treatments.

The goal is to help participants absorb and "integrate" their experience. It typically happens over two or more sessions of 60 to 90 minutes with a therapist. In some cases, the therapist may invite a significant other to join in the integration process.

Agrawal's trial at the Bill Richards center added something new: group therapy. Not only did Bansal meet with his therapist, he also met with a group of three other people in the trial who had their dosing the same day.

The point, says Agrawal, is to try and determine the effect of the group on the therapy. After their private dosing sessions, they come back together to discuss their experiences.

"After the psilocybin, they feel like they've been to war together," Agrawal says. "There is this profound openness and connection. They feel able to share things with each other that they wouldn't with other people."

It will take some time to figure out how the group affects the overall outcome, but Bansal thinks it was integral to the success of his treatment.

In fact, he continues to meet regularly with his therapy group, even though it's long since past the requirements of the study.

Pradeep 2.0

Bansal still has tough days with his cancer. Recently, immunotherapy treatment for his bladder caused side effects -- pain, bleeding, fever, and chills -- for most of the night. He felt like he was "passing razor blades" when he peed.

"And yet it was somehow OK," he says. "It was only pain."

"It's as if there is a part of me that is watching myself objectively, going through the painful process of treatments saying, 'It's all right. I will be with you through this journey, through this experience. Don't worry.'"


Months after taking that one dose, Bansal still calls it as "the single most powerful experience of my life."

The change in his mental outlook, Bansal says, was profound, particularly in regard to his cancer.

"I understood that I still had cancer and that it could kill me in a few weeks, or months, or years. But my perspective had shifted."

Bansal was as surprised as anyone.

"Had somebody told me going into this that I would come out a transformed being or a person with a completely different perspective on life, I would never have believed it."

He even named his new outlook. "I call it Pradeep 2.0."

 
Last edited:
Cancer_skin_credit_flickr-Zeiss.jpg



Cannabinoids as a potential cancer treatment

Beckley Foundation | 19 Mar 2022

In collaboration with Profs Manuel Guzman and Guillermo Velasco at Madrid Complutense University, we plan to investigate the anti-cancer properties of cannabis and its individual cannabinoids, with the aim of establishing the most effective combination of cannabinoids. Together with the Spanish Group of Neurooncology (GEINO), Profs Guzman and Velasco will conduct a clinical trial in 4 centres in Spain. In this study, patients with newly diagnosed glioblastoma (brain tumour) will receive cannabinoids in combination with traditional anticancer drugs and radiation therapy. Results will help clarify the question of whether cannabinoids can be used to fight cancer.

This programme is investigating the anti-cancer properties of cannabis and individual cannabinoids, such as THC and CBD, that have been found to exhibit anti-tumour effects in a wide array of animal models and in vitro studies of cancer. Together with the Spanish Neurooncology Group GEINO, we are now preparing to conduct a clinical trial to test whether cannabinoids can help fight tumour growth in cancer patients.

ijms-20-01673-ag-550.jpg


How cannabinoids may help cure cancer

1. They are Anti-proliferative, meaning they prevent cancer cells from reproducing. Cannabinoids have been shown to possess anti-proliferative effects in vitro as well as in vivo in different cancer models.

2. They are Anti-angiogenic, meaning they prevent formation of new blood vessels needed by tumors to grow. Cannabinoids inhibit tumor growth in laboratory animals by inducing apoptosis (programmed cell death) of tumor cells and impairing tumor angiogenesis.

3. They are Anti-metastatic, meaning they prevent cancer from spreading to other organs. Cannabinoids decrease cancer cell migration. Cannabinoids decrease matastasis in various tumor types in laboratory animals.

4. They are Apoptotic, meaning they induce cancer cells to seek their own death. Treatment with a cannabis compound reduced the viability and invasiveness of treated tumor cells in vitro and induced apoptosis.

http://beckleyfoundation.org/science...ctions/cancer/
 
human-people-person-bed-furniture.jpg



Could psychedelics be the next breakthrough treatment for cancer patients' mental health?

by Erin Marie | Health Digest | 5 Apr 2022

Up to 35% of cancer patients experience mental health difficulties in conjunction with a cancer diagnosis, according to 2020 research published in Epidemiology and Psychiatric Sciences. While not formally recognized as a mental health disorder, an additional 15% to 20% of cancer patients experience existential distress, such as a loss of meaning or spiritual morale.

Psilocybin, a chemical derived from a type of mushroom native to areas of the U.S., Mexico, and Central America, is known for its hallucinatory effects in humans when ingested (via the Drug Enforcement Administration). While psilocybin, or magic mushrooms, is legal in the U.S., it is classified as a Schedule I substance under the Controlled Substances Act and, therefore, is not approved for accepted medical use.

Over the years, the number of scientific studies looking at the clinical potential of psilocybin and other psychedelics to relieve mental health-related stress has grown. Although the study is still underway, a new series of clinical trials show promise in the use of psilocybin as a potential treatment method for major depressive disorder in cancer patients. Oncologist Manish Agrawal, principal investigator on one of the clinical trials, shares via The Washington Post how doses of psilocybin appear to affect cancer patients experiencing anxiety or depression related to their cancer diagnosis.

Psilocybin shown to reduce death anxiety in cancer patients

Agrawal explains how two patients in the clinical trial experienced a mindset shift around mortality while using the psychedelic that resulted in decreases in mental and emotional distress (via The Washington Post). Overall, in 15 out of 30 patients, clinical depression symptoms were gone after a period of eight weeks following treatment with a single dose of psilocybin in combination with therapy.

Such evidence appears to be in alignment with alternate studies, such as a long-term follow-up study conducted by researchers at the NYU Grossman School of Medicine. Researchers found that more than four years after a one-time dose of psilocybin, cancer patients experienced decreases in death anxiety, hopelessness, and depression.

Experts believe the mental health-boosting effects of psychedelics may be due to their potential to rewire the brain. According to 2021 research cited in the World Journal of Psychiatry, " ... psychedelic agents may induce rapid synaptic plasticity, and this plasticity may be a key mechanism by which they can exert long-term antidepressant effects." Some scientists believe approval for the use of psychedelics in the treatment of clinical depression in cancer patients is not far off (via KUER). Dr. Anna Beck, director of the Huntsman Cancer Institute, states via KUER, "Psychedelic medicine is the only thing that has been shown to make a difference in terms of alleviating some of the existential distress."

 
R-DOI_chemical_structure.png


Is (R)-DOI a super-potent anti-cancer medicine?*

Pharmacological Review | 6 Mar 2022

(R)-DOI (2,5-Dimethoxy-4-iodoamphetamine) is a psychedelic first synthesized by Alexander Shulgin. It is a potent inhibitor of Tumor Necrosis Factor-a inflammation, which exerts strong anti-cancer and anti-inflammatory effects through the modulation of innate and adaptive immune processes. (R)-DOI seems to be a superpower in regulating the 5HT2a receptor to inhibit TNF-α-mediated inflammation in the body. Activation of the 5-HT2A receptor represents a novel and extraordinarily potent therapeutic avenue for treating chronic inflammatory conditions, infections and cancer.

(R)-DOI is a psychedelic and mixed 5-HT2A/5-HT2C receptor agonist which acts via 5-HT2A receptors to inhibit the inflammatory effects of tumor necrosis factor (TNF)-α. Tumor necrosis factor-alpha (TNF)-α plays a key role in inflammation, and its production and signaling contribute to many inflammatory related diseases. Recently, we discovered that selective activation of serotonin 5-HT2A receptors with the agonist (R)-DOI produces a super-potent blockade of pro-inflammatory markers. Here we demonstrate that systemic administration of (R)-DOI can block the systemic effects of (TNF)-α in whole animal. Importantly, the mechanism underlying the systemic anti-inflammatory effects of (R)-DOI is activation of serotonin 5-HT2A receptors. Our results highlight a powerful new role for the serotonin 5-HT2A receptor in inflammatory processes, and indicate that agonism of serotonin receptors may represent an effective and novel approach to develop powerful small molecule therapeutics for inflammatory diseases.

*From the article here: http://pharmrev.aspetjournals.org/co...2/264.full.pdf
 
'Tumors just vanished'

UNHEARD OF: Cancer drug trial shows full remission





Experimental treatment made rectal cancer tumors disappear in small trial group

by Sacha Pfeiffer | NPR | 27 Jun 2022

Treatment with the immunotherapy dostarlimab showed promising results in a small trial of more than a dozen rectal cancer patients, according to new research, but further study is needed and it is too early to call it a cure. CNN's Erin Burnett speaks to Dr. Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Center.

A tiny group of people with rectal cancer just experienced something of a miracle - their cancer simply vanished after an experimental treatment. In a very small trial, these patients took a drug called dostarlimab for six months, and in the end, every one of them saw their tumors disappear. Now, this trial was small - just 18 people - and there's still more to be learned about how the treatment worked. But some scientists say these kinds of results have never been seen in the history of cancer research.

So to talk more about this is Dr. Hanna Sanoff of the University of North Carolina's Lineberger Comprehensive Cancer Center. She's not involved with the study. That was done by doctors with New York's Memorial Sloan Kettering Cancer Center. But Dr. Sanoff has written about the results. Welcome to the program.

HANNA SANOFF: Thank you.

PFEIFFER: Now, we are typically very cautious about focusing on studies that are so tiny, but there has been so much cautious enthusiasm about this that we wanted to talk about it. Could you tell us your reaction when you heard about the results?

SANOFF: Absolutely. I mean, I am incredibly optimistic. Like you said in the introduction, we have never seen anything work in 100% of people in cancer medicine.

PFEIFFER: We should note, I believe, that with rectal cancer, some cases can involve chemo, radiation, surgery, maybe a combination of all of those. How does this drug work?

SANOFF: This drug is one of a class of drugs called immune checkpoint inhibitors. And these are immunotherapy medicines that work not by directly attacking the cancer itself but actually getting a person's immune system to essentially do the work. And these are drugs that have been around in melanoma and other cancers for quite a while but really have not been part of the routine care of colorectal cancers until fairly recently.

PFEIFFER: And typically, drugs have side effects. What kinds of side effects were there with this one?

SANOFF: Very, very few in this study - in fact, surprisingly few. Most people had no severe adverse effects at all.

PFEIFFER: You've said before that this clinical trial is practice-changing for the field. In what way do you view it as practice-changing?

SANOFF: Well, our hope would be that for this subgroup of people - which is, I think we should point out, only about 5% to 10% of people who have rectal cancer - if they can go on and just get six months of immunotherapy and not have any of the rest of this - I don't even know the word to use. Paradigm shift is often used, but this really absolutely is paradigm-shifting.

PFEIFFER: I do want to emphasize that we often cheer for people when we hear that they have kicked cancer. But the aftermath of what they can deal with physically and side effects can still be life-changing, which is why the idea of being able to skip surgery is so revolutionary.

SANOFF: Yes. In rectal cancer, this is part of the conversation we have with someone when they're diagnosed - is, you know, we are very hopeful for being able to cure you, but unfortunately, we know our treatments are going to leave you with consequences that may, in fact, be life-changing. I mean, I have had patients who, after their rectal cancer, have barely left the house for years - and in a couple of cases, even decades - because of the consequences of incontinence and the shame that's associated with this.

PFEIFFER: Have you ever had patients that said they've regretted getting the treatment?

SANOFF: You bet.

PFEIFFER: Really?

SANOFF: Yeah.

PFEIFFER: So if this drug ends up being as good as it preliminarily seems to be, what's the next step?

SANOFF: What I'd really like us to do is get a bigger trial where this drug is used in a much more diverse setting to understand what the real, true response rate's going to be. It's not going to end up being 100%. I hope I bite my tongue on that in the future, but I can't imagine it will be 100%. And so when we see what the true response rate is, that's when I think we can really do this all the time.

PFEIFFER: That's Dr. Hanna Sanoff of the University of North Carolina's Lineberger Comprehensive Cancer Center. Thank you very much.

SANOFF: Thank you.
 
Last edited:
Top